Clinical trial
Sequential Adjuvant Chemotherapy With Doxorubicin, Taxol, and Cyclophosphamide for Stage II or III Resectable Breast Cancer With Four or More Involved Axillary Lymph Nodes
NCT00002679 is registered in ClinicalTrials.gov with Yale University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Sequential Adjuvant Chemotherapy With Doxorubicin, Taxol, and Cyclophosphamide for Stage II or III Resectable Breast Cancer With Four or More Involved Axillary Lymph Nodes
- Lead sponsor
- Yale University
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 28, 1994
- Completion date
- January 31, 2002
- Enrollment
- 89 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer